MTCR Metacrine Inc.

8.5
-0.23  -3%
Previous Close 8.73
Open 8.54
52 Week Low 8.05
52 Week High 16.19
Market Cap $220,628,550
Shares 25,956,300
Float 17,812,835
Enterprise Value $141,048,523
Volume 39,023
Av. Daily Volume 154,400
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
MET642
Healthy volunteers
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
MET409
Nonalcoholic steatohepatitis (NASH)
Phase 1b
Phase 1b
Phase 1b data presented at AASLD meeting November 2020.

Latest News

  1. SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the following December investor conferences:

    • Piper Sandler 32nd Annual Virtual Healthcare Conference (fireside chat) being held December 1-3, 2020. Company presentations will be available for registered attendees on the Piper Sandler conference site from November 23 to December 3. Metacrine will participate in 1x1 meetings with investors during the conference on Wednesday, December 2, 2020.
    • Evercore…

    SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the following December investor conferences:

    • Piper Sandler 32nd Annual Virtual Healthcare Conference (fireside chat) being held December 1-3, 2020. Company presentations will be available for registered attendees on the Piper Sandler conference site from November 23 to December 3. Metacrine will participate in 1x1 meetings with investors during the conference on Wednesday, December 2, 2020.
    • Evercore ISI 3rd Annual HealthCONx (fireside chat) on Thursday, December 3, 2020 at 3:55 p.m. ET/12:55 p.m. PT. Metacrine will participate in 1x1 meetings with investors during the conference on Thursday, December 3, 2020.

    Webcasts of the presentations will be available in the investor section of the company's website at www.metacrine.com. The webcasts will be archived for 60 days following the presentations.

    About Metacrine

    Metacrine, Inc. (NASDAQ:MTCR) is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. The company's most advanced programs, MET409 and MET642, target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. Both MET409 and MET642 are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH).

    Contact:

    Chelcie Lister

    THRUST Strategic Communications

    910.777.3049



    Primary Logo

    View Full Article Hide Full Article
  2. Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH

    $85 Million Initial Public Offering Completed

    SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today reported recent business highlights and third quarter 2020 financial results.

    "2020 has been a transformational year for Metacrine, as we advanced the development of our proprietary FXR platform, including our MET409 and MET642 clinical programs, and made the important transition into a publicly traded company," said Preston Klassen…

    Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH

    $85 Million Initial Public Offering Completed

    SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today reported recent business highlights and third quarter 2020 financial results.

    "2020 has been a transformational year for Metacrine, as we advanced the development of our proprietary FXR platform, including our MET409 and MET642 clinical programs, and made the important transition into a publicly traded company," said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. "As we look to the rest of the year, we plan to present new data from our MET409 Phase 1b proof-of-concept clinical trial in patients with NASH at AASLD, which further support the continued advancement of these potential best-in-class FXR programs. Additionally, we have selected the antidiabetic agent, an SGLT-2 inhibitor, to be evaluated with MET409 in our planned combination trial, which is on-track to initiate in the first half of next year. With additional capital and an established leadership team of talented industry veterans, we stand in a strong position to continue advancing both MET409 and MET642, while also exploring additional opportunities in our early-stage pipeline to expand our portfolio and support our future growth."

    Program Highlights

    • New MET409 Data to be Presented at AASLD's The Liver Meeting Digital Experience: Two posters highlighting pharmacokinetic and pharmacodynamic data along with early prediction of longer term changes in liver fat content on the company's lead clinical candidate, MET409, a farnesoid X receptor (FXR) agonist for the treatment of non-alcoholic steatohepatitis (NASH), will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting Digital Experience™. The virtual meeting is taking place November 13-16, 2020.

       
    • SGLT-2 Inhibitor Selected as Combination Agent for MET409 Phase 2a Combination Trial: Metacrine has selected empagliflozina sodium-glucose cotransport-2 (SGLT-2) inhibitor, to be evaluated in combination with MET409 in the company's planned Phase 2a clinical trial for the treatment of patients with both NASH and type 2 diabetes. SGLT-2 inhibitors, in addition to affording glycemic control and cardiovascular/renal benefits, have demonstrated positive effects on liver fat reduction. A daily oral combination treatment with an FXR agonist and SGLT-2 inhibitor could be beneficial for patients with NASH and type 2 diabetes, who are believed to be at a greater risk of liver disease progression. The company anticipates beginning the combination trial in the first half of 2021.

       
    • Positive MET409 Phase 1b Clinical Data in NASH Patients Presented at the Digital International Liver Congress™ 2020: In August, Metacrine presented positive, final results from its 12-week, randomized, placebo-controlled Phase 1b study of MET409 in patients with NASH in a late-breaking poster presentation as part of the Digital International Liver Congress. In the Phase 1b proof-of-concept trial, 58 patients with NASH were randomized 1:1:1 to receive oral, once-daily MET409 at 50 mg or 80 mg, or to placebo. Study findings show that MET409 meaningfully lowered and normalized liver fat content compared to placebo with a reassuring safety and tolerability profile. The full findings can be seen here.



    • MET409 Received FDA Fast Track Designation for the Treatment of NASH: In August, Metacrine announced that the FDA granted Fast Track designation to MET409 for the treatment of NASH. Fast Track is a process designed to facilitate the development and expedite the review of drugs designed to treat serious diseases or conditions and that have the potential to fill an unmet medical need for such diseases or conditions. This designation was granted to MET409 based on data from a completed Phase 1b study in NASH patients as well as preclinical studies.

    Recent Business Highlights

    • Successful Initial Public Offering (IPO) Completed: On September 15, 2020, Metacrine sold 6,540,000 shares of its common stock at a public offering price of $13.00 per share. The gross proceeds to Metacrine from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Metacrine, were approximately $85.0 million.

    Anticipated Milestones

    • Metacrine expects to announce topline results from its Phase 1 clinical study in healthy volunteers of MET642 before the end of 2020.

    Upcoming Investor Conference Presentation

    Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will participate in a fireside chat during the Jefferies Virtual London Healthcare Conference on Thursday, Nov. 19, 2020 at 7:20 p.m. GMT/11:20 a.m. PT.

    The live webcast will be available in the investor section of the company's website at www.metacrine.com. The webcast will be archived for 60 days following the presentation.

    Third Quarter Financial Results

    • Cash Balance: Cash, cash equivalents and short-term investments were $109.2 million as of September 30, 2020, which includes $85.0 million in gross proceeds from the company's IPO completed in September 2020.



    • R&D Expenses: Research and development (R&D) expenses were $6.2 million for the three months ended September 30, 2020, as compared to $7.6 million for the same period in the prior year. The decrease in research and development expenses was primarily attributable to manufacturing, preclinical and toxicology work performed during 2019 to support the initiation of the Phase 1 clinical trial of MET642 in March 2020.

       
    • G&A Expenses: General and administrative (G&A) expenses were $2.7 million for the three months ended September 30, 2020, as compared to $1.1 million for the same period in the prior year. The increase in general and administrative expenses was primarily attributable to increased headcount and non-cash stock-based compensation charges.



    • Net Loss: Net loss was $9.1 million for the three months ended September 30, 2020, as compared to $8.5 million for the same period in the prior year.

    About Metacrine

    Metacrine, Inc. (NASDAQ:MTCR) is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. The company's most advanced programs, MET409 and MET642, target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. Both MET409 and MET642 are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH).

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the therapeutic potential of MET409 and MET642; statements regarding Metacrine's timelines; the differentiated nature of Metacrine's FXR program; plans underlying Metacrine's clinical trials; plans for advancing the clinical development of Metacrine's FXR program; the potential best-in-class nature of Metacrine's FXR program; and the potential for its FXR product candidates to be long-term therapies for NASH; and the potential benefits of MET409's Fast Track designation. Words such as "may," "will," "expect," "plan," "aim," "anticipate," "estimate," "intend," "potential," "prepare" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Metacrine's expectations and assumptions that may never materialize or prove to be incorrect. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks and uncertainties regarding regulatory approvals for MET409 or MET642; potential delays in initiating, enrolling or completing any clinical trials; potential adverse side effects or other safety risks associated with Metacrine's product candidates; competition from third parties that are developing products for similar uses; and Metacrine's ability to obtain, maintain and protect its intellectual property. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in Metacrine's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 12, 2020, and in Metacrine's other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as required by law, Metacrine assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

    Contact:

    Chelcie Lister

    THRUST Strategic Communications

    910.777.3049

    Metacrine, Inc.

    Unaudited Condensed Consolidated Statements of Operations

    (In thousands, except per share data)

      Three Months Ended  Nine Months Ended 
      September 30,  September 30, 
      2020  2019  2020  2019 
    Operating expenses:                
    Research and development $6,217  $7,647  $19,973  $19,497 
    General and administrative  2,693   1,069   6,087   3,057 
    Total operating expenses  8,910   8,716   26,060   22,554 
    Loss from operations  (8,910)  (8,716)  (26,060)  (22,554)
    Total other income (expense)  (144)  251   (428)  1,018 
    Net loss $(9,054) $(8,465) $(26,488) $(21,536)
    Net loss per share, basic and diluted $(1.41) $(3.51) $(6.89) $(9.17)
    Weighted average shares of common stock outstanding, basic and diluted  6,436,546   2,409,227   3,845,793   2,349,635 





    Metacrine, Inc.

    Unaudited Condensed Consolidated Balance Sheets

    (In thousands)

      September 30,  December 31,
      2020  2019
    Assets       
    Current assets:       
    Cash, cash equivalents, and short-term investments $109,239  $55,651 
    Prepaid expenses and other current assets  1,663   1,692 
    Total current assets  110,902   57,343 
    Property and equipment, net  690   735 
    Operating lease right-of-use asset  1,740   2,203 
    Total assets $113,332  $60,281 
    Liabilities, Convertible Preferred Stock, and Stockholders' Equity (Deficit)        
    Current liabilities:       
    Accounts payable $655  $239 
    Accrued and other current liabilities  3,447   4,149 
    Total current liabilities  4,102   4,388 
    Long-term debt, net of debt discount  9,309   9,099 
    Other long-term liabilities  1,758   2,566 
    Convertible preferred stock  -   122,465 
    Stockholders' equity (deficit)  98,163   (78,237)
    Total liabilities, convertible preferred stock, and stockholders' equity (deficit) $113,332  $60,281 





    Metacrine, Inc.

    Unaudited Condensed Consolidated Statements of Cash Flows

    (In thousands)

      Nine Months Ended 
      September 30, 
      2020  2019 
    Operating activities:        
    Net loss $(26,488) $(21,536)
    Non-cash adjustments  4,025   1,505 
    Changes in operating assets and liabilities  (1,658)  1,361 
    Net cash used in operating activities  (24,121)  (18,670)
    Investing activities:        
    Purchases of property and equipment  (172)  (56)
    Proceeds from short-term investments  29,089   11,398 
    Net cash provided by investing activities  28,917   11,342 
    Financing activities:        
    Proceeds from issuance of common stock from initial public offering, net of issuance costs  77,750   - 
    Proceeds from issuance of long-term debt, net of issuance cost  -   9,717 
    Proceeds from other financing activities  67   29 
    Net cash provided by financing activities  77,817   9,746 
    Net increase in cash and cash equivalents  82,613   2,418 
    Cash and cash equivalents at beginning of period  15,668   15,965 
    Cash and cash equivalents at end of period $98,281  $18,383 

    Primary Logo

    View Full Article Hide Full Article
  3. SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that two posters highlighting new data on the company's lead clinical candidate, MET409, a farnesoid X receptor (FXR) agonist for the treatment of non-alcoholic steatohepatitis (NASH), will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting Digital Experience™. The virtual meeting is taking place Nov. 13-16, 2020.

    "We are pleased to report new pharmacokinetic and pharmacodynamic data from our MET409 Phase 1b proof-of-concept clinical trial in…

    SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that two posters highlighting new data on the company's lead clinical candidate, MET409, a farnesoid X receptor (FXR) agonist for the treatment of non-alcoholic steatohepatitis (NASH), will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting Digital Experience™. The virtual meeting is taking place Nov. 13-16, 2020.

    "We are pleased to report new pharmacokinetic and pharmacodynamic data from our MET409 Phase 1b proof-of-concept clinical trial in patients with NASH, a prevalent and potentially life-threatening condition for which there are no approved treatments available today," said Hubert C. Chen, M.D., chief medical officer of Metacrine. "The findings demonstrated robust and sustained FXR activation, which we believe is key to optimizing therapeutic benefits. Combined with a favorable pharmacological and tolerability profile, these results further highlight the therapeutic potential of MET409 for patients with NASH. We look forward to presenting these data, which support the continued advancement of our FXR program, including both MET409 and our second clinical candidate, MET642."

    In addition, new data generated in collaboration with Dr. Mustafa R. Bashir, associate professor of Radiology and associate professor in the Department of Medicine, Gastroenterology, and colleagues at Duke University Medical Center, show that relative liver fat content (LFC) reduction after four weeks of treatment with MET409 was strongly predictive of LFC reduction at week 12 in the proof-of-concept study. "These findings suggest that early measurement of liver fat content may help guide the long-term treatment strategy with FXR agonists in NASH," said Dr. Bashir.

    Title: Dose-dependent changes in pharmacokinetic and pharmacodynamic profiles of MET409, a sustained FXR agonist, after 12 weeks of treatment in patients with NASH

    Authors: E.J. Lawitz, K-J Lee, J. Shim-Lopez, J. Lee, H.C. Chen

    Publication Number: 1669

    Session Title: NAFLD and NASH: Therapeutics - Pharmacologic and Other

    Key Findings: In a 12-week, randomized, double-blind, placebo-controlled study, 58 patients diagnosed with NASH were enrolled into three cohorts: 50 mg (n=19), 80 mg (n=20) and placebo (n=19). MET409 treatment resulted in dose-dependent decreases in serum levels of C4, a circulating biomarker of FXR target activity: 71-95% in trough levels at day 84 relative to baseline, and 78-96% in day 84 area-under-the-curve (AUC) relative to placebo (p<0.05 for both comparisons). These results demonstrate robust, sustained FXR activation by MET409 and correlate with previously-reported benefits of LFC reduction and improvement in liver chemistries.

    Title: Change in liver fat content at 4 weeks accurately predicts change in liver fat content at 12 weeks in non-alcoholic steatohepatitis patients treated with an FXR Agonist: Analysis from a 12-week, randomized, placebo-controlled study with MET409

    Authors: H. Jiang, H.C. Chen, K.J. Lafata, M.R. Bashir

    Publication Number: 1489

    Session Title: NAFLD and NASH: Diagnostics and Biomarkers

    Key Findings: As previously reported, MET409 significantly lowered LFC at week 12, with mean relative reductions of 55% (80 mg) and 38% (50 mg) vs. 6% in placebo (p<0.001). MET409 achieved ≥30% relative LFC reduction in 93% (80 mg) and 75% (50 mg) of patients vs. 11% in placebo (p<0.001). Simple and multiple linear regression analyses demonstrated that week 4 relative LFC reduction (regression coefficient: 1.243, p<0.001) was a significant predictor of week 12 LFC reduction. These findings suggest the potential of early liver fat content assessment as an indicator of long-term treatment response.

    About Metacrine

    Metacrine, Inc. (NASDAQ:MTCR) is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. The company's most advanced programs, MET409 and MET642, target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. Both MET409 and MET642 are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH).

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "aim," "anticipate," "estimate," "intend," "potential," "prepare" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the therapeutic potential of MET409, plans for advancing the clinical development of our FXR program and the potential for our FXR product candidates to be long-term therapies for NASH. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies and uncertainties related to the regulatory approval path for the NASH indication. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the company's filings with the U.S. Securities and Exchange Commission, including "Risk Factors" section of the company's prospectus dated September 15, 2020 filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission. Except as required by law, the company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

    Contact:

    Chelcie Lister

    THRUST Strategic Communications

    910-777-3049

    Primary Logo

    View Full Article Hide Full Article
View All Metacrine Inc. News